Results 261 to 270 of about 214,405 (338)
Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer [PDF]
Crowder, Robert +12 more
core +1 more source
Interpreting pathways to discover cancer driver genes with Moonlight [PDF]
al., et +2 more
core +1 more source
This study identifies ADP‐ribosylation factor‐like protein 3 (ARL3) as a novel chaperone that stabilizes estrogen receptor α (ERα) in breast cancer. ARL3 promotes tumor growth by recruiting USP10 to remove ubiquitin chains from ERα, preventing its degradation.
Han Li +14 more
wiley +1 more source
Pathology image-based predictive model for individual survival time of early-stage lung adenocarcinoma patients. [PDF]
Vo VT, Yang HJ, Lee T, Kim SH.
europepmc +1 more source
Neoadjuvant gemcitabine plus nab‐paclitaxel (AG) reprograms pancreatic ductal adenocarcinoma by shifting malignant cells toward a classical phenotype and remodeling the tumor microenvironment. Despite enhancing cytotoxic NKT cells, AG activates tumor‐associated mast cells (TAMCs) and inflammatory CAFs through MIF signaling.
Libo Wang +16 more
wiley +1 more source
Integrative analysis of single-cell and transcriptome RNA sequencing to establish a NAT10-related signature for prognostic prediction of uveal melanoma. [PDF]
Liu W, Xu Y.
europepmc +1 more source
LZU‐WZLYCS01 is a novel FGFR3‐targeting ADC for bladder cancer with 7‐ethyl‐9‐fluorocamptothecin (A2) as its cytotoxic payload. LZU‐WZLYCS01 intracellularly releases A2, which targets MAD2L1 to activate the cGAS‐STING pathway and induce tumor cell apoptosis.
Shu Cui +16 more
wiley +1 more source
Invasive Lobular Carcinoma Has Higher Immune Response Than Invasive Ductal Carcinoma in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers. [PDF]
Yee G, Wu R, Ishikawa T, Takabe K.
europepmc +1 more source

